23andMe Holding Co. (ME)
0.74
-1.05 (-58.66%)
At close: Mar 24, 2025, 3:59 PM
0.70
-5.78%
After-hours: Mar 24, 2025, 07:59 PM EDT
-58.66% (1D)
| Bid | 0.7 |
| Market Cap | 19.95M |
| Revenue (ttm) | 212.56M |
| Net Income (ttm) | -389.81M |
| EPS (ttm) | -17.39 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.07 |
| Analyst | Hold |
| Ask | 0.72 |
| Volume | 6,606,377 |
| Avg. Volume (20D) | 291,712 |
| Open | 0.92 |
| Previous Close | 1.79 |
| Day's Range | 0.73 - 0.97 |
| 52-Week Range | 0.73 - 12.76 |
| Beta | 1.20 |
About ME
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact respo...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Nov 23, 2020
Employees 560
Stock Exchange NASDAQ
Ticker Symbol ME
Website https://www.23andme.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ME stock is "Hold." The 12-month stock price forecast is $9.4, which is an increase of 1164.29% from the latest price.
Stock Forecasts1 day ago
23andMe shares are trading lower after the company...
Unlock content with
Pro Subscription
3 weeks ago
-33.18%
23andMe shares are trading lower after the company announced that New Mountain is no longer interested in acquiring the company. CEO Anna Wojcicki has submitted a proposal via a 13D filing to buy the remaining shares not already owned.
